EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access

Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana

Roger L Shapiro iD, Gbolahan Ajibola iD, Kenneth Maswabi iD, Michael Hughes, Bryan S Nelson iD, Aischa Niesar iD, Molly Pretorius Holme, Kathleen M Powis iD, Maureen Sakoi iD, Oganne Batlang, Sikhulile Moyo iD, Terence Mohammed und 20 weitere

Science Translational Medicine · 05.07.2023 · 15 (703)

DOI: 10.1126/scitranslmed.adh0004 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Science Translational Medicine, erschienen am 05.07.2023. Verfasst von Roger L Shapiro und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA. Hauptthemen laut MEDLINE: HIV Infections, HIV-1. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, FIC NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Broadly neutralizing antibodies (bNAbs) may provide an alternative to standard antiretroviral treatment (ART) for controlling HIV-1 replication and may have immunotherapeutic effects against HIV-1 reservoirs. We conducted a prospective clinical trial with two HIV-1 bNAbs (VRC01LS and 10-1074) in children ( n = 25) who had previously initiated small-molecule ART treatment before 7 days of age and who continued treatment for at least 96 weeks. Both bNAbs were dosed intravenously every 4 weeks, overlapping with ART for at least 8 weeks and then continued for up to 24 weeks or until detectable viremia of HIV-1 RNA rose above 400 copies per milliliter in the absence of ART. Eleven (44%) children maintained HIV-1 RNA below 400 copies per milliliter through 24 weeks of bNAb-only treatment; 14 (56%) had detectable viremia above 400 copies per milliliter at a median of 4 weeks. Archived HIV-1 provirus susceptible to 10-1074, lower birth HIV-1 DNA reservoir in peripheral blood mononuclear cells, sustained viral suppression throughout early life, and combined negative qualitative HIV-1 DNA polymerase chain reaction and negative HIV-1 serology at entry were associated with maintaining suppression on bNAbs alone. This proof-of-concept study suggests that bNAbs may represent a promising treatment modality for infants and children living with HIV-1. Future studies using newer bNAb combinations with greater breadth and potency are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHIV-1ChildHumansAnti-Retroviral AgentsAntibodies, NeutralizingBotswanaBroadly Neutralizing AntibodiesHIV AntibodiesLeukocytes, MononuclearProspective StudiesViremia

Substanzen

Anti-Retroviral AgentsAntibodies, NeutralizingBroadly Neutralizing AntibodiesHIV Antibodies

Autor:innen und Institutionen

  • Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.
  • Botswana Harvard Health Partnership, Gaborone, Botswana.
  • Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.
  • Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Departments of Internal Medicine and Pediatrics, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Bennett Statistical Consulting Inc., Ballston Lake, NY 12019, USA.

ORCID-Profile: Roger L Shapiro, Gbolahan Ajibola, Kenneth Maswabi, Bryan S Nelson, Aischa Niesar, Kathleen M Powis, Maureen Sakoi, Sikhulile Moyo, Comfort Maphorisa, Kara Bennett, Ce Gao, Xu Yu, Margaret E Ackerman, Adrian McDermott, Marlene Cooper, Marina Caskey, Lucio Gama, Dwight E Yin, Edmund V Capparelli, Shahin Lockman, Mathias Lichterfeld

Förderung

  • NIAID NIH HHS
  • FIC NIH HHS

Zitieren

APA

Shapiro, R. L., Ajibola, G., Maswabi, K., Hughes, M., Nelson, B. S., Niesar, A., Pretorius Holme, M., Powis, K. M., Sakoi, M., Batlang, O., Moyo, S., Mohammed, T., Maphorisa, C., Bennett, K., Hu, Z., Giguel, F., Reeves, J. D., Reeves, M. A., Gao, C., …, & Lichterfeld, M. (2023). Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana. Science Translational Medicine, 15(703). https://doi.org/10.1126/scitranslmed.adh0004

Vancouver

Shapiro RL, Ajibola G, Maswabi K, Hughes M, Nelson BS, Niesar A, et al. Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana. Science Translational Medicine. 2023;15(703). doi:10.1126/scitranslmed.adh0004

BibTeX
@article{Shapiro2023,
  author = {Shapiro, Roger L and Ajibola, Gbolahan and Maswabi, Kenneth and Hughes, Michael and Nelson, Bryan S and Niesar, Aischa and Pretorius Holme, Molly and Powis, Kathleen M and Sakoi, Maureen and Batlang, Oganne and Moyo, Sikhulile and Mohammed, Terence and Maphorisa, Comfort and Bennett, Kara and Hu, Zixin and Giguel, Francoise and Reeves, Jacqueline D and Reeves, Michael A and Gao, Ce and Yu, Xu and Ackerman, Margaret E and McDermott, Adrian and Cooper, Marlene and Caskey, Marina and Gama, Lucio and Jean-Philippe, Patrick and Yin, Dwight E and Capparelli, Edmund V and Lockman, Shahin and Makhema, Joseph and Kuritzkes, Daniel R and Lichterfeld, Mathias},
  title = {Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana},
  journal = {Science Translational Medicine},
  year = {2023},
  volume = {15},
  number = {703},
  doi = {10.1126/scitranslmed.adh0004}
}
Kostenlos starten →